Overview
Sumitomo Pharma America develops and sells prescription medicines for patients with cancer, bladder conditions, women's health disorders and other serious illnesses. Its portfolio combines established treatments with research into diseases that have limited treatment options. The business carries medicines from scientific development and clinical studies through manufacturing and commercialization, with approved products prescribed by healthcare professionals. It operates as the consolidated U.S. pharmaceutical business within Japan's Sumitomo Pharma group. The company traces its roots to 1984, took its combined form in 2023 and is headquartered in Marlborough, Massachusetts.
Work here?Claim your company
Simplify's take
What believers are saying
- SMPA invites all employees to Insights Discovery assessments, using a four-color framework to examine communication styles and personality.
- SMPA's full-time Great Plains liaisons receive 80 paid sick-leave hours upon hire and annually.
- Employees report satisfaction: SMPA's August 2026 certification announcement says 89% considered it a great place to work.
What critics are saying
- SMPA's displayed pipeline lacks late-stage trials: its listed programs are in Phases 1 or 2.
- Heavy travel accompanies remote work: SMPA's Great Plains medical science liaisons travel domestically over 50% in full-time roles.
- RETHYMIC addresses a tiny market: SMPA estimates congenital athymia affects 17-24 U.S. newborns annually.
What makes Sumitomo Pharma America unique
- SMPA certifies manufacturing information security: its program holds the international ISO 27001 information-security certification.
- RETHYMIC requires individual manufacturing: SMPA makes its donor-thymus treatment for one child at a time.
- SMPA's regenerative research spans brain and eye disorders: its pipeline includes Parkinson's disease and retinitis pigmentosa.
Help us improve and share your feedback! Did you find this helpful?